ГЕМАФЕР-С,розчин для ін’єкцій, Містрал Кепітал Менеджмент Лімітед, Англія

Communication materials on the safe use of the medicinal product EYLEA® (aflibercept). Risk minimization in the use of the medicinal product

Communication materials on the safe use of the medicinal product EYLEA® (aflibercept) for patients

On the submission of periodic safety update reports (PSURs) using the new cover letter template

Changes to the safety information of medicinal products containing aflibercept following the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) of 06 – 09 July 2026

Changes to the safety information of medicinal products containing aflibercept following the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) of 06 – 09 July 2026

Competitive selection of members of the HTA Expert Committee: deadline for submitting documents – until 12 October 2026

Updated! List of original (innovative) medicinal products registered in Ukraine as of 07.09.2026

Attention to business entities engaged in retail trade of medicinal products on the market of Ukraine! We provide lists of over-the-counter medicinal products by their storage conditions